Intra-Cellular Therapies Management
Management criteria checks 2/4
Intra-Cellular Therapies' CEO is Sharon Mates, appointed in May 2002, has a tenure of 21.92 years. total yearly compensation is $9.23M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €73.30M. The average tenure of the management team and the board of directors is 5.5 years and 10.3 years respectively.
Key information
Sharon Mates
Chief executive officer
US$9.2m
Total compensation
CEO salary percentage | 9.2% |
CEO tenure | 21.9yrs |
CEO ownership | 1.0% |
Management average tenure | 5.5yrs |
Board average tenure | 10.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$140m |
Sep 30 2023 | n/a | n/a | -US$155m |
Jun 30 2023 | n/a | n/a | -US$184m |
Mar 31 2023 | n/a | n/a | -US$228m |
Dec 31 2022 | US$9m | US$849k | -US$256m |
Sep 30 2022 | n/a | n/a | -US$298m |
Jun 30 2022 | n/a | n/a | -US$321m |
Mar 31 2022 | n/a | n/a | -US$304m |
Dec 31 2021 | US$7m | US$794k | -US$284m |
Sep 30 2021 | n/a | n/a | -US$259m |
Jun 30 2021 | n/a | n/a | -US$237m |
Mar 31 2021 | n/a | n/a | -US$232m |
Dec 31 2020 | US$5m | US$767k | -US$227m |
Sep 30 2020 | n/a | n/a | -US$207m |
Jun 30 2020 | n/a | n/a | -US$187m |
Mar 31 2020 | n/a | n/a | -US$160m |
Dec 31 2019 | US$5m | US$745k | -US$148m |
Sep 30 2019 | n/a | n/a | -US$148m |
Jun 30 2019 | n/a | n/a | -US$155m |
Mar 31 2019 | n/a | n/a | -US$154m |
Dec 31 2018 | US$4m | US$723k | -US$155m |
Sep 30 2018 | n/a | n/a | -US$145m |
Jun 30 2018 | n/a | n/a | -US$126m |
Mar 31 2018 | n/a | n/a | -US$106m |
Dec 31 2017 | US$5m | US$702k | -US$98m |
Compensation vs Market: Sharon's total compensation ($USD9.23M) is above average for companies of similar size in the German market ($USD3.42M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
CEO
Sharon Mates (70 yo)
21.9yrs
Tenure
US$9,232,857
Compensation
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 21.9yrs | US$9.23m | 1.02% $ 73.3m | |
President | less than a year | US$3.48m | 0% $ 0 | |
Executive VP & Chief Medical Officer | 5.7yrs | US$3.46m | 0.019% $ 1.4m | |
EVP & Chief Commercial Officer | 5.5yrs | US$3.50m | 0.028% $ 2.0m | |
Senior VP & Chief Scientific Officer | 8.4yrs | US$2.13m | no data | |
Vice President of Corporate Communications & Investor Relations | 10.1yrs | US$1.38m | no data | |
Senior VP & Chief Compliance Officer | 4.8yrs | no data | no data | |
Senior VP & Head of Regulatory Affairs | 5.6yrs | no data | no data | |
Senior VP of Market Access | 5.1yrs | no data | no data | |
Senior VP & Head of Clinical Development | 2yrs | no data | no data |
5.5yrs
Average Tenure
60yo
Average Age
Experienced Management: 23I's management team is seasoned and experienced (5.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 10.7yrs | US$9.23m | 1.02% $ 73.3m | |
Independent Director | 10.3yrs | US$741.17k | 0.094% $ 6.8m | |
Lead Independent Director | 10.3yrs | US$774.41k | 0.0092% $ 663.8k | |
Independent Director | 10.7yrs | US$743.26k | 0.038% $ 2.7m | |
Chairman of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Independent Director | 2yrs | US$716.63k | 0% $ 0 |
10.3yrs
Average Tenure
70yo
Average Age
Experienced Board: 23I's board of directors are seasoned and experienced ( 10.3 years average tenure).